Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection (Neptuno)

A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 Infection

Treatment of patients hospitalised for management of moderate COVID-19 infection

Study Overview

• Status: Terminated
• Conditions: COVID-19 Infection
• Intervention / Treatment: Drug: Plitidepsin; Drug: Dexamethasone; Drug: Remdesivir; Drug: Favipiravir

Detailed Description

This is a multicentre, open-label, controlled Phase 3 study in which adults requiring hospital admission and O2 supplementation for management of moderate COVID-19 infection will be randomised in 1:1:1 to: Plitidepsin 1.5 mg arm, Plitidepsin 2.5 mg arm and Control arm

• Study Type: Interventional
• Enrollment (Actual): 205
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • MG
    • Belo Horizonte, MG, Brazil, 30110-934
      • Hospital Felicio Rocho
• Bulgaria
  • Sofia, Bulgaria, 1570
    • "MHAT "Sveta Anna"" - Sofia AD
• Colombia
  • Atlántico
    • Barranquilla, Atlántico, Colombia, 80020
      • Clínica de la costa Ltda.
• France
  • Tours, France, 37044
    • Centre Hospitalier Regional et Universitaire de Tours (CHRU Tours) - Hopital Bretonneau
• Greece
  • Athens, Greece, 106 76
    • Evangelismos Hospital General Hospital of Athens Evangelismos, Intensive Care Unit
  • Athens, Greece, 115 27
    • Sotiria Hospital General Hospital of Chest Diseases of Athens "Sotiria" 3rd Department of Internal Medicine of University of Athens
• Mexico
  • NL
    • Monterrey, NL, Mexico, 64460
      • Universidad Autonoma de Nuevo Leon - Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
• Romania
  • Bucharest, Romania, 021105
    • Institutul National De Boli Infectioase "Prof. Dr. Matei Bals"
  • Bucharest, Romania, 030303
    • Spitalul Clinic de Boli Infectioase si Tropicale Dr. Victor Babes - Bucharest
  • Iaşi, Romania, 700116
    • Spitalul Clinic De Boli Infectioase "Sfanta Parascheva" IASI, Sectia Boli Infectioase III
  • Suceava, Romania, 720237
    • Spitalul Judetean de Urgenta 'Sf. Ioan cel Nou' Suceava, Sectia de Boli Infectioase
• Spain
  • Alicante, Spain, 3010
    • Hospital General Universitario de Alicante
  • Granada, Spain, 18014
    • Hospital Universitario Virgen de las Nieves (HUVN)
  • Guadalajara, Spain, 19002
    • Hospital Universitario de Guadalajara
  • Madrid, Spain, 28034
    • Hospital Universitario Ramon y Cajal
  • Madrid, Spain, 28040
    • Hospital Clinico San Carlos
  • Madrid, Spain, 28032
    • Hospital Infanta Leonor
  • Madrid, Spain, 28050
    • H. HM Sanchinarro
  • Madrid, Spain, 28055
    • Hospital de Emergencias Enfermera Isabel Zendal
  • Salamanca, Spain, 37007
    • Hospital Universitario de Salamanca
  • Santander, Spain, 39008
    • Instituto de Investigación Sanitaria Valdecilla (IDIVAL)
  • Sevilla, Spain, 41013
    • Hospital Universitario Virgen del Rocío
  • Barcelona
    • Badalona, Barcelona, Spain, 08916
      • Hospital Universitari Germans Trias i Pujol
    • Hospitalet de Llobregat, Barcelona, Spain, 08907
      • Hospital Universitari de Bellvitge
  • Cádiz
    • Jerez De La Frontera, Cádiz, Spain, 11407
      • Hospital Universitario de Jerez de la Frontera
  • Madrid
    • Boadilla Del Monte, Madrid, Spain, 28668
      • Hospital Universitario HM Montepríncipe
    • Pozuelo De Alarcón, Madrid, Spain, 28223
      • Hospital Quironsalud Madrid
  • Pontevedra
    • Vigo, Pontevedra, Spain, 36213
      • Hospital Alvaro Cunqueiro

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed informed consent obtained prior to initiation of any study-specific procedures and study treatment.
2. Documented diagnosis of SARS-CoV-2 infection, determined by either qualitative polymerase chain reaction (PCR), antigen test by local laboratory, or any other validated method approved by the local health authority, from appropriate biological samples collected no more than 72 hours prior to study treatment on Day 1.
3. Patient meets category 5 on the 11-point WHO Clinical Progression Scale: requires hospitalisation and oxygen by mask or nasal prongs/cannula.
4. A maximum of 14 days from onset of COVID-19 symptoms to initiation of study treatment on Day 1.
5. Male or female aged ≥18 years.

6. Adequate bone marrow, liver, kidney, and metabolic function, defined by the following tests performed at local laboratory:

   • Absolute neutrophil count ≥500/mm^3 (0.5 x 10^9/L).
   • Platelet count ≥75,000/mm^3 (75 x 10^9/L).
   • Alanine transaminase (ALT), aspartate transaminase (AST) ≤3 x upper limit of normal (ULN).
   • Serum bilirubin ≤1 x ULN (or direct bilirubin <1 x ULN when total bilirubin is above ULN).
   • Calculated creatinine clearance ≥30 mL/min (Cockcroft-Gault equation).
   • Creatine phosphokinase (CPK) ≤2.5 x ULN except if the patient has had recent (i.e., in the last week) shivering episodes or trauma. In that case, the level of CPK should be ≤5 x ULN.
7. Agree not to participate in another interventional clinical trial through Day 31.
8. Females of reproductive capacity must have a negative serum or urine pregnancy test by local laboratory at study enrolment and must be non-lactating.
9. Females and males with partners of child-bearing potential must use effective contraception while on study treatment and for 6 months after last dose of plitidepsin. Patients in the control arm must use effective contraception during the time indicated in the approved product information (summary of product characteristics [SmPC] or leaflet). If no information is available in the approved product information, patients in the control arm must use effective contraception for at least one week after the study completion or the time indicated based on the investigator's discretion.

Exclusion Criteria:

1. Subjects with a pre-baseline (i.e., in the month preceding the current COVID-19 infection) impairment in general health condition for whatever reason except COVID-19, with a severe dependency for daily living activities (Barthel index ≤ 60/100) or chronic oxygen therapy.
2. Having received treatment for COVID-19 in another clinical trial in the prior 4 weeks, except documented allocation in a placebo arm.
3. Evidence of respiratory failure at the time of randomisation, based on resource utilisation requiring at least one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, non-invasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (i.e., clinical need for one of the aforementioned therapies, which could not be administered in a resource-limited setting).
4. Patients with severe COVID-19, meeting score >5 on the 11-point WHO Clinical Progression Scale or presenting, after an initial stabilisation prior to randomisation, any of clinical signs indicative of severe systemic illness, such as respiratory rate ≥30 per minute, heart rate ≥125 per minute, or PaO2/FiO2 <300. In case a direct measure of PaO2 has not been obtained, it should be imputed according to a referenced formula. For sites located over 1000 m above sea level, PaO2/FiO2 ratio will be adjusted.

5. Patients receiving, at randomisation, treatment with antiviral therapy against SARS-CoV-2 or requiring anti-inflammatory/immunomodulating drugs beyond glucocorticoids with the exceptions listed below:

   • Prior administration of dexamethasone or equivalent glucocorticoid might be acceptable if:

     1. The total daily dose is not higher than 10 mg of dexamethasone phosphate (equivalent to dexamethasone base 8.25 mg/day) or equivalent glucocorticoids.
     2. The duration of the treatment does not exceed 72 hours prior to study treatment Day 1.

   • Prior administration of dexamethasone or equivalent glucocorticoid might be acceptable if:

     1. The total daily dose is not higher than 10 mg of dexamethasone phosphate (equivalent to dexamethasone base 8.25 mg/day) or equivalent glucocorticoids.
     2. The duration of the treatment does not exceed 72 hours prior to study treatment Day 1.

   • Prior administration of an antiviral might be acceptable in the following circumstances:

     1. For small molecules (e.g., remdesivir, molnupiravir, nirmaltrevir/ritonavir), they must have been given for an earlier stage of the disease, outside a clinical trial, and there should be a documentation of objective clinical deterioration plus evidence of persisting positivity for SARS-CoV-2 in appropriate biological samples. Last dose of previous antiviral drugs should have been administered at least 24 h before randomisation.
     2. For antiviral monoclonal antibodies, they must have been given for an earlier stage of the disease (including pre-exposure prophylaxis), outside a clinical trial, and there should be a documentation of objective clinical deterioration plus evidence of persisting positivity for SARS-CoV-2 in appropriate biological samples. Last dose of antiviral monoclonal antibodies should have been administered at least 1 week before randomisation.
6. Patients receiving treatment with chloroquine or derivatives within 8 weeks before enrolment or during the study.
7. Patients receiving treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.
8. Viral illness (other than COVID-19) requiring therapy, except for patients with treated and adequately controlled (undetectable) human immunodeficiency virus infection.
9. Patients with uncontrolled known primary or secondary immunodeficiency, including chronic treatment with glucocorticoids (i.e., prednisone at a daily dose of >10 mg for >1 month, or another glucocorticoid at equipotent dose).

10. Any of the following cardiac conditions or risk factors:

    • Sinus bradycardia (<50 beats/min), sinus nodal dysfunction (sick sinus disease), atrioventricular block of any degree (PR >200 msec), or any other bradyarrhythmia (<50 beats/min), except for patients with permanent pacemakers;
    • Cardiac infarction, cardiac surgery or cardiac insufficiency episode within the last 6 months;
    • Known abnormal value of left ventricular ejection fraction (LVEF <low limit of normal (LLN)), unless documented confirmation of recovery (LVEF >LLN) in the previous month;
    • QT interval corrected using Fridericia's formula (QTcF) >450 msec for males or >470 msec for females;
    • History of known congenital or acquired QT prolongation;
    • Uncorrected hypokalaemia, hypocalcaemia (adjusted) and/or hypomagnesemia at screening;
    • Troponin test performed at local laboratory >1.5 x ULN; or
    • Need for an unreplaceable drug that prolongs QT and it is clearly associated with a known risk for torsades de pointes (TdP); in case of being already on treatment with these aforementioned drugs, a minimum of 4 half-lives of the drug is required before replacement (if feasible).
11. Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol) or patients for whom dexamethasone, antihistamine H1/H2 or antiserotoninergic agents are contraindicated.
12. Females who are pregnant (negative serum or urine pregnancy test required for all females of child-bearing potential at screening) or breast feeding.
13. Females and males with partners of child-bearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who are not using at least 1 protocol specified method of contraception.
14. Any other clinically significant medical condition (including major surgery within the last 3 weeks before screening) or laboratory abnormality that, in the opinion of the investigator, would jeopardise the safety of the patient or potentially impact on patient compliance or the safety/efficacy observations in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Plitidepsin 1.5 mg arm; Patients will receive plitidepsin 1.5 mg/day intravenous (IV) in addition to dexamethasone on days 1 to 3.	Drug: Plitidepsin; Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial. Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule. For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes.; Drug: Dexamethasone; Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Experimental: Plitidepsin 2.5 mg arm; Patients will receive plitidepsin 2.5 mg/day IV in addition to dexamethasone on days 1 to 3.	Drug: Plitidepsin; Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial. Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule. For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes.; Drug: Dexamethasone; Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Active Comparator: Control arm; Patients will receive dexamethasone IV on Days 1 to 3. Additionally, in accordance with local treatment guidelines, patients in this group may receive a regulatory-approved antiviral treatment.	Drug: Dexamethasone; Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.; Drug: Remdesivir; Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.; Drug: Favipiravir; Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Sustained Withdrawal of Supplementary Oxygen With no Subsequent Reutilisation During Remaining Study Period	Time to sustained withdrawal of oxygen supplementation (in days) with no subsequent reutilisation during remaining study period is defined as the first day, from randomisation through completion of the study, on which a patient i. satisfies categories 0 to 4 on the 11-point WHO Clinical Progression Scale, and ii. has no subsequent reutilisation of oxygen supplementation (5 to 10 on the 11-point WHO Clinical Progression Scale). The WHO clinical progression scale provides a measure of illness severity across a range from 0 (uninfected) to 10 (dead).	From administration date to Day 31(±3)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Sustained (i.e., With no Subsequent Readmission to Day 31) Hospital Discharge (Since Randomisation).	Time to sustained (i.e., with no subsequent readmission to Day 31) hospital discharge (since randomization)	From administration date to Day 31(±3)
Clinical Status by the 11-category WHO Clinical Progression Scale on Day 8	The WHO clinical progression scale provides a measure of illness severity across a range from 0 (uninfected) to 10 (dead). 0 = Uninfected; no viral RNA detected; = Ambulatory mild disease. Asymptomatic; viral RNA detected; = Ambulatory mild disease. Symptomatic; independent; = Ambulatory mild disease. Symptomatic; assistance needed; = Hospitalized: moderate disease. Hospitalized; no oxygen therapy; = Hospitalized: moderate disease. Hospitalized; oxygen by mask or nasal prongs; = Hospitalized: severe diseases. Hospitalized; oxygen by NIV or high flow; = Hospitalized: severe diseases. Intubation and mechanical ventilation pO2/FIO2 > 150 or SpO2/FIO2 > 200; = Hospitalized: severe diseases. Mechanical ventilation pO2 /FIO2 <150 (SpO2 /FiO2 <200) or vasopressors; = Hospitalized: severe diseases. Mechanical ventilation pO2 /FiO2 <150 and vasopressors, dialysis, or ECMO; = dead	Day 8 (±1)
Total Duration of Advanced Oxygen Support	Total duration of advanced oxygen support (high-flow nasal oxygen, extracorporeal membrane oxygenation -ECMO-, non-invasive ventilation or mechanical ventilation).	From administration date to Day 31(±3)
Number of Participants in Each Study Group Requiring Admission to ICU	Number of participants in each study group requiring admission to intensive care unit	Day 4, Day 8(±1) , Day 15(±1) and Day 31(±3)
Frequency of Adverse Events	Adverse Event Types according to the National Cancer Institute [NCI]-Common Terminology Criteria for AEs (CTCAE v.5.0): The number of participants who experienced treatment-emergent adverse events (TEAEs) are presented.	From administration date to Day 31(±3)
Frequency of TEAEs of ≥Grade 3 According to NCI-CTCAE for Adverse Events (Version 5.0), TEAEs of Special Interest, Serious TEAEs, Serious Treatment-related TEAEs, TEAEs Leading to Treatment Discontinuation, and Deaths	Frequency of treatment-emergent adverse events (TEAEs) of ≥grade 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 5.0), TEAEs of special interest, serious TEAEs, serious treatment-related TEAEs, TEAEs leading to treatment discontinuation, and deaths	From administration date to Day 31(±3)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients in each study group who require hospital readmission related to COVID-19		From administration date to Day 31(±3)
Percentage of patients in each study group and in each of the categories of the 11-point WHO Clinical Progression Scale	Percentage of patients in each study group requiring oxygen therapy, requiring non-invasive mechanical ventilation and requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The WHO clinical progression scale provides a measure of illness severity across a range from 0 (uninfected) to 10 (dead).	Day 4, Day 8(±1), Day 15(±1) and Day 31(±3)
Time to intensification of respiratory support (WHO >6 [intubation])	The WHO clinical progression scale provides a measure of illness severity across a range from 0 (uninfected) to 10 (dead).	From administration date to Day 31(±3)
Total duration of intensive care unit (ICU) stay for each study group.		From administration date to Day 31(±3)
Time to initiation with immune-modulating drugs		From administration date to Day 31(±3)
Time to initiation with antiviral drugs		From administration date to Day 31(±3)
Percentage of patients receiving subsequent immune-modulating drugs		Day 4, Day 8(±1), Day 15(±1), and Day 31(±3)
Percentage of patients receiving subsequent antiviral drugs		Day 4, Day 8(±1), Day 15(±1), and Day 31(±3)
Percentage of patients in each study group with nosocomial infection		Day 4, Day 8(±1), Day 15(±1), and Day 31(±3)
Mortality in each study group		Day 4, Day 8(±1), Day 15(±1), and Day 31(±3)
Change in the viral load of acute respiratory distress syndrome due to coronavirus 2 (SARS-CoV-2) [copies/mL] in each study group		Day 1 before administration of the study drug until Day 8(±1)
Percentage of patients in each study group with undetectable viral load of SARS-CoV-2		Day 8(±1)
Efficacy: Change from baseline in inflammatory biomarkers	Proinflammatory biomarkers: C-reactive protein (CRP) [mg/L], ferritin [ng/L], IL-1β [pg/mL], IL-6 [pg/mL], IL-10 [pg/mL] and tumour necrosis factor alpha (TNFα) [pg/mL]	From baseline until Days 2, 3, 4, Day 8(±1), and Day 31(±3)
Efficacy: Change from baseline in serological SARS CoV 2 testing (immunoglobulin [Ig]G) [UA/ml]		Day 1 and Day 31(±3)
To compare efficacy in the primary endpoint and describe safety/tolerability of pooled plitidepsin arms versus control: Time to sustained withdrawal of supplementary oxygen with no subsequent reutilisation during remaining study period	Time to sustained withdrawal of supplementary oxygen (as defined by the WHO clinical progression scale (Score ≤4)). The WHO clinical progression scale provides a measure of illness severity across a range from 0 (uninfected) to 10 (dead).	From administration date to Day 31(±3)
To compare efficacy in the primary endpoint and describe safety/tolerability between plitidepsin arms (1.5 versus 2.5 mg): Time to sustained withdrawal of supplementary oxygen with no subsequent reutilisation during remaining study period	To compare efficacy in the primary endpoint and describe safety/tolerability between plitidepsin arms (1.5 versus 2.5 mg) in case both are significantly superior to the control. Time to sustained withdrawal of supplementary oxygen (as defined by the WHO clinical progression scale (Score ≤4). The WHO clinical progression scale provides a measure of illness severity across a range from 0 (uninfected) to 10 (dead).	From administration date to Day 31(±3)
To explore the influence of risk factors or scores for clinical deterioration that were not individually included; Obesity, hypertension, age and individual co-morbidities included in the Charlson Index, ISARIC-4C score or vaccination status.		From administration date to Day 31(±3)
Time to sustained sustained withdrawal of supplementary oxygen with no subsequent reutilisation during remaining study period, before (protocol v.6) and after the amendment (protocol v.7).	Time to sustained withdrawal of supplementary oxygen (as defined by the WHO clinical progression scale (Score ≤4). The WHO clinical progression scale provides a measure of illness severity across a range from 0 (uninfected) to 10 (dead).	From administration date to Day 31(±3)
Time to sustained (i.e., with no subsequent readmission to Day 31) hospital discharge (since randomisation), before (protocol v.6) and after the amendment (protocol v.7).		From administration date to Day 31(±3)
Substudy only: Change from baseline in electrocardiogram (ECG) findings	Electrocardiogram (ECG) findings: heart rate, QTc, QRS, waveform morphology-related measurements and QTc for whole blood concentrations of plitidepsin (ng/ml)	0, 1, 2.5, 5, 24, 25, 26.5, 29, 48, and 49 hours
Substudy only: Whole blood clearance of plitidepsin		0, 1, 2.5, 5, 24, 25, 26.5, 29, 48, 49 and 72 hours
Substudy only: Whole blood area under curve (AUC) of plitidepsin		0, 1, 2.5, 5, 24, 25, 26.5, 29, 48, 49 and 72 hours

Collaborators and Investigators

• Sponsor: PharmaMar
• Investigators: Study Director: José Jimeno Doñaque, MD, PhD, PharmaMar

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2021
• Primary Completion (Actual): March 1, 2023
• Study Completion (Actual): March 1, 2023

Study Registration Dates

• First Submitted: March 4, 2021
• First Submitted That Met QC Criteria: March 4, 2021
• First Posted (Actual): March 5, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 29, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Respiratory Tract Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; COVID-19; Infections; Communicable Diseases; Anti-Infective Agents; Antineoplastic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antimetabolites; Antiviral Agents; Remdesivir; Dexamethasone; Favipiravir
• Other Study ID Numbers: APL-D-003-20; 2020-005951-19 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No